Description of drug utilization and assessment of impact of Saxagliptin on health status of patients with type 2 diabetes in France - DIAPAZON
Study identifier:CV181-148
ClinicalTrials.gov identifier:NCT01552005
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Description of drug utilization and assessment of impact of Saxagliptin on health status of patients with type 2 diabetes in France
Medical condition
Type 2 diabetes mellitus (T2D)
Phase
-
Healthy volunteers
No
Study drug
Saxagliptin
Sex
All
Actual Enrollment
1000
Study type
Observational
Age
18 Years +
Date
Study Start Date: 01 May 2012
Primary Completion Date: 01 Jun 2015
Study Completion Date: 01 Jun 2015
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jun 2016 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Population of patients treated with Saxagliptin | Drug: Saxagliptin No Intervention |
Contacts
Contact Backup
First line of email MUST contain NCT# & Site#. Only trial site that are recruiting have contact information at this time
-
-
Investigators
Principal Investigator
Bristol-Myers Squibb
Bristol-Myers Squibb
